TALK KEYWORD INDEX
This page contains an index consisting of author-provided keywords.
A | |
acute and chronic rejection | |
Acute leukemia | |
acute lymphoblastic leukemia | |
Acute myeloid leukemia | |
acute rejection | |
adaptive immune responses | |
admixed population | |
adoptive T-cell immunotherapy | |
adverse drug reaction | |
African ancestry | |
ageing | |
aGvHD | |
AI & Big data transforming medical research | |
Allocation | |
Allogeneic Hematopoietic Cell Transplantation | |
allogeneic hematopoietic stem cell transplantation | |
allogeneic stem cell transplantation | |
allograft rejection | |
alloreactivity | |
Analysis of MHC in Pangenome and thousand genome data | |
ancestry | |
Antiretroviral therapy | |
Artificial intelligence | |
Association | |
autoimmune disease | |
autoimmune diseases | |
Autoimmunity | |
B | |
B cell memory | |
B7H7 | |
Best Abstract Awards | |
Best Poster Awards | |
big data | |
Big Data Modeling | |
bioethical regulation | |
Bioinformatics | |
biology of CD8+ Tregs | |
biomarker | |
Blood Groups | |
BM microenvironment | |
Bone Marrow Transplantation | |
breast cancer | |
BW4 | |
C | |
C4 | |
Cancer Evolution | |
CAR T-cell | |
carbamazepine hypersensitivity | |
Carcinoma cervix | |
causative mechanisms | |
CD4+ T cells | |
CD8+ T cells | |
cell therapy | |
Cellular therapies | |
Ceppellini Lecture | |
cfDNA | |
cGvHD | |
chimerism | |
Chimpanzee | |
chimpanzees | |
classical HLA alleles | |
Closing Ceremony | |
Closing Remarks | |
CMV | |
Committee meeting | |
common diseases | |
Complement Component 4 | |
complex loci | |
Copy Number Variation | |
Cord Blood | |
core permissive | |
Coverage | |
COVID-19 | |
COVID-19 severity | |
Cryptic immunopeptidome | |
Crystal Structure | |
Cytomegalovirus (CMV) | |
D | |
dd-cfDNA | |
de novo assembly | |
decidual immune cell | |
Decision-making | |
DEG | |
Deletion | |
differential expression | |
disease association | |
disease outcome | |
diversity | |
DNA | |
donor-derived cell-free DNA | |
droplet digital PCR | |
DSA | |
Duplication | |
E | |
EBMT | |
Education | |
EFI | |
Epitope | |
Eplet | |
Epstein-Barr Virus | |
ESOT | |
European ancestry | |
European collaborations ethical framework | |
Evolution | |
evolutionary divergence | |
expression levels | |
F | |
French bioethics law | |
Full-gene sequencing | |
G | |
Gene expression profile | |
gene ontology | |
gene regulatory networks | |
Genetics bioethical regulation in France | |
Genome wide survival study | |
Genomic | |
Genomic Organization | |
Genotyping | |
Genotyping array | |
Graft biopsy | |
graft-versus-host disease | |
GVHD | |
GWAS | |
H | |
Haematopoietic cell transplantation | |
HAPLO-iPS | |
haploidentical donor selection | |
Haploidentical hematopoietic stemcell transplantation | |
Haplotype | |
HED | |
hematopoietic cell transplantation | |
hematopoietic stem cell transplantation | |
heterologous immunity | |
HHLA2 | |
HIV | |
HLA | |
HLA association | |
HLA Award | |
HLA class I | |
HLA class I epitopes | |
HLA class II | |
HLA E | |
HLA evolutionary divergence | |
HLA evolutionary divergence (HED) | |
HLA immunogenicity | |
HLA ligands | |
HLA loss | |
HLA matched related and unrelated donors | |
hla matching | |
HLA mismatch | |
HLA molecular matching | |
HLA*57:01 | |
HLA-A*02:01 B*18:01 DRB*03 extended haplotype | |
HLA-B | |
HLA-Bw4 | |
HLA-C | |
HLA-DM | |
HLA-DO | |
HLA-DP | |
HLA-DP binding motif | |
HLA-DPB1 | |
HLA-DPB1*13 | |
HLA-DRB1 | |
HLA-E | |
Host genetic factors | |
hsa-mir-7111-5p | |
HSCT | |
HSCT complications | |
human cytomegalovirus | |
Human Induced Pluripotent Stem Cells | |
human populations | |
human reference genome | |
humoral immune responses | |
humoral response | |
I | |
IEL | |
IFN-α antibodies | |
IHIWS | |
IHIWS +365 Report | |
imaging mass cytometry | |
Immune diseases | |
Immune diversity | |
Immune escape | |
immune pathways | |
immune reconstitution | |
Immune responses | |
Immune system | |
immune-mediated traits | |
Immunogenecity | |
Immunogenetic diversity | |
Immunogenetics | |
immunogenetics of ageing | |
Immunogenicity | |
immunoglobulin | |
Immunology | |
Immunopeptidome | |
immunotherapies | |
Immunotherapy | |
impuatation | |
Imputation | |
Indirect allorecognition | |
Infection | |
Innovation in Transplantation | |
J | |
Jon Van Rood Award | |
Julia Bodmer Award | |
K | |
Kidney pair donation | |
Kidney Transplantation | |
Killer cell immunoglobulin-like receptors | |
KIR | |
KIR association | |
KIR gene organization | |
KIR2DS4 | |
KIR3DL2 | |
KIR3DL3 | |
L | |
Leukemia relapse | |
liquid biopsy | |
liver transplantation | |
lncRNAs | |
Location of HLA-Y | |
long read sequencing | |
lung transplantation | |
lupus | |
M | |
Macaque | |
machine learning | |
Major histocompatibility locus | |
match | |
matching | |
memory cells | |
memory HLA specificity | |
MHC | |
MHC Class I | |
MHC diversity | |
MHC evolution | |
MICA | |
Microbial Genomics | |
microRNAs | |
minor histocompatibility antigens | |
Mismatches | |
mRNA vaccine | |
Multiple Myeloma | |
Multiple Sclerosis | |
Multivirus | |
Myocarditis | |
N | |
naive T-cell depletion | |
nanoporen | |
Nanostring | |
NAT | |
Neanderthal Covid-19 risk haplotype | |
New MHC class I sequence similar to HLA-P and HLA-W | |
Next Generation Sequencing | |
NGS | |
NK | |
NK cell diversity | |
NK cells | |
Non-classical HLA | |
non-core permissive | |
novel KIR alleles | |
null allele | |
O | |
oocyte donation | |
Opening Ceremony | |
organ transplantation | |
Oxford Nanopore Technologies sequencing | |
P | |
pairing algorithm | |
Pan-European registries | |
PANS | |
Pediatric Acute-Onset Neuropsychiatric Syndrome | |
pediatric heart transplantation | |
peptide-binding | |
Peptidome Analysis | |
permissive mismatches | |
Pfizer-BioNTech BNT162b2 vaccination | |
PGAE | |
philosophical analysis | |
philosophy | |
PIRCHE-II | |
Plasmodium falciparum | |
Polymorphism | |
Population Frequency | |
Population Genetics | |
population groups | |
population reference graph | |
Population Structure | |
post-transplant DSA treatment | |
Post-Transplant Lymphoproliferative Disease | |
pre-transplant desensitization | |
Precision Medicine | |
Prediction | |
Promoter regions | |
proteome | |
R | |
Recipient Specific Antibodies (RSA) | |
Recombination | |
Regulation | |
Regulatory B cells | |
Regulatory T cells | |
Rejection | |
relapse | |
Renal transplantation | |
Repertoire profiling | |
Retrospecive study | |
RNA | |
RNA sequensing | |
RNA-seq | |
RPL | |
S | |
SARS-CoV-2 | |
Scientific Committee | |
Selection | |
Sequence assembly | |
Sequencing | |
SFHI | |
SHLARC | |
SIP | |
SMRT DNA sequencing | |
software | |
Solid Organ Transplantation | |
Soluble HLA E | |
spike | |
stem cell transplantation | |
Stem cells bioethical regulation in France | |
survival analysis | |
systemic autoimmune diseases | |
systems immunology | |
T | |
T cell | |
T cell receptor | |
T cell receptor repertoire | |
T cells | |
T-cell epitope | |
T-cell epitopes | |
T-Cell Receptor Engineering | |
T-cell receptors | |
T-cell-mediated rejection | |
TCR | |
Telemedicine | |
telomeres | |
Tranplantation | |
transcriptome | |
Transgene expression | |
Transmissible Cancer | |
Transplantation | |
Transplantation legal regulation in France | |
tumor biology | |
U | |
unrelated donor | |
V | |
Vaccination | |
Vaccine response | |
Variant calling | |
Variegated expression | |
Viral infection | |
Virological failure | |
Virus specific T cell | |
W | |
Welcome Addresses | |
whole genome sequencing | |
γ | |
γδ T cells |